 |
|
|
| |
A Phase II Study of Samatasvir (IDX719) in Combination with Simeprevir and Ribavirin in Treatment-Naďve HCV-Infected Subjects with Genotypes 1b and 4 (HELIX-1 Study)
|
| |
| |
Reported by jules Levin
EASL 2014 April 9-13 London, UK
Lawitz, E1, Rodriguez-Torres, M2, Nguyen, T3, Sheikh, A4, Tobias, H5, Galati, J6, Hill, J7, Lok, A8, Nelson, D9, G. Dubuc Patrick10, J. Chen10, D. Frank10, X.J. Zhou10, J. Z. Sullivan-Bólyai10, P. Van Remoortere11, R. Verloes12, G. Picchio11, D. Mayers10 and the HELIX-1 Investigator Group
1Texas Liver Institute, San Antonio, Texas; 2Fundacion de Investigacion de Diego, Santurce, PR; 3San Diego, California; 4Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia; 5Concorde Medical Group PLLC, New York, New York; 6Research Specialists of Texas, Houston, Texas;
7Avail Clinical Research, LLC, Deland, Florida; 8University of Michigan Health System, Ann Arbor, Michigan; 9University of Florida-Shands, Gainesville, Florida; 10Idenix Pharmaceuticals, Inc., Cambridge, MA; 11Janssen Research and Development, Titusville, NJ; 12Janssen Infectious Diseases BVBA, Beerse, Belgium
IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects......http://www.natap.org/2013/HCV/013113_03.htm
|
| |
|
|
|
|
|
